Japan approves remdesivir as Covid-19 treatment

USA. In this March 2020 photo provided by Gilead Sciences, rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (AP)
USA. In this March 2020 photo provided by Gilead Sciences, rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (AP)

TOKYO -- Japan has approved Gilead Sciences’ antiviral drug remdesivir for coronavirus treatment in a fast-track review just four days after the US company submitted an application.

The drug is the first approved in Japan for the coronavirus. It was originally developed for Ebola and could block the coronavirus from replicating itself in the human body.

It will mainly be used for seriously ill patients. It was authorized by the US Food and Drug Administration for coronavirus treatment last Friday.

Japan is also testing a Japanese-made influenza drug, favipiravir, that is also designed to inhibit viral replication but could cause birth defects.

Prime Minister Shinzo Abe is pushing for favipiravir and says he hopes to have it approved by the end of May for less serious patients. (AP)

Trending

No stories found.

Just in

No stories found.

Branded Content

No stories found.
SunStar Publishing Inc.
www.sunstar.com.ph